Educational content on VJOncology is intended for healthcare professionals only. By visiting this website and accessing this information you confirm that you are a healthcare professional.

Share this video  

BTOG 2021 | Inequalities in biomarker testing

Alastair Greystoke • 23 Apr 2021
BTOG 2021
Breast Cancer General Lung Cancer

Alastair Greystoke, MBChB, MSc, PhD, MRCP, Northern Institute for Cancer Research, Newcastle University, Newcastle, UK, talks on inequalities in access to biomarker testing and targeted treatments. Patients with lung cancer who were from a poorer socioeconomic background were found to have worse access to biomarker testing. This interview took place during the 19th British Thoracic Oncology Group (BTOG) Annual Conference 2021.

Disclosures

Alastair Greystoke, MBChB, MSc, PhD, MRCP, has received consultancy and speaker fees from AstraZeneca, Amgen, Boehringer-Ingelheim, Bristol-Myers Squibb, Janssen/ J and J, Foundation Medicine, MSD, Novartis, Pfizer, Lilly, Takeda and Roche; and has received research funding from AstraZeneca.

More from Alastair Greystoke

6:20
Solid tumor genomic testing in the UK: challenges and solutions
Alastair Greystoke • 28 Apr 2023
1:51
NHS England: a pilot ctDNA study to track patient responses to novel genomic targets
Alastair Greystoke • 27 Apr 2023
5:59
Deciphering an NGS report in lung cancer
Alastair Greystoke • 24 Jan 2022
3:34
Strategies to improve biomarker testing in the UK
Alastair Greystoke • 24 Jan 2022

Related Videos

0:29
Innovative ctDNA-based liquid biopsy techniques for cancer diagnosis
Alain Thierry • 9 Apr 2024
0:50
Employing fragmentomics as a novel strategy to characterize and detect cancers
Alain Thierry • 9 Apr 2024
1:27
Emerging trials in melanoma: SWOG S1801, OpACIN-neo and PRADO
Christoffer Gebhardt • 9 Apr 2024
2:38
Phase I trial of binimetinib and pembrolizumab in NSCLC
Natasha Leighl • 17 Apr 2024
The content of VJOncology is intended for healthcare professionals